PCRX Q4 2022 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$172M+8.0% YoY

Gross Profit

$110M64.0% margin

Operating Income

-$10M-5.8% margin

Net Income

-$10M-5.9% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+2.7%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$37M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$906M

Stockholders' Equity

$775M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$172M	$159M	+8.0%
Gross Profit	$110M	$120M	-8.4%
Operating Income	-$10M	$4M	-334.9%
Net Income	-$10M	-$5M	-96.9%

Revenue Segments

Product

$172M86%

ZILRETTA

$28M14%

Bupivacaine Liposome Injectable Suspension

$1M1%